Stockreport

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology, Inc.  (VIR) 
PDF – Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs –– Phase 3 ECLIPSE registrational progra [Read more]